Glesatinib companion diagnostic - Guardant Health/Mirati TherapeuticsAlternative Names: MGCD-265 companion diagnostic
Latest Information Update: 28 Apr 2016
At a glance
- Originator Guardant Health
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Head and neck cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 17 Mar 2014 Clinical trials in Non-small cell lung cancer (diagnosis) in USA (unspecified route)
- 17 Mar 2014 Clinical trials in Solid tumours (diagnosis) in Canada and USA (unspecified route)